Novel Pitolisant-Derived Sulfonyl Compounds for Alzheimer Disease.

Alzheimer's disease (AD) is a complex and multifactorial neurodegenerative disorder characterized by cognitive decline, memory loss, behavioral changes, and other neurological symptoms. Considering the urgent need for new AD therapeutics, in the present study we designed, synthesized, and evaluated multitarget compounds structurally inspired by sulfonylureas and pitolisant with the aim of obtaining multitarget ligands for AD treatment. Due to the diversity of chemical scaffolds, a novel strategy has been adopted by merging into one structure moieties displaying HR antagonism and acetylcholinesterase inhibition. Eight compounds, selected by their binding activity on HR, showed a moderate ability to inhibit acetylcholinesterase activity in vitro, and two of the compounds (derivatives and ) were also capable of increasing acetylcholine release in vitro. Among the tested compounds, derivative was identified and selected for further in vivo studies. Compound was able to reverse scopolamine-induced cognitive deficits with results comparable to those of galantamine, a drug used in clinics for treating AD. In addition to its efficacy, this compound showed moderate BBB permeation in vitro. Altogether, these results point out that the fragment-like character of compound leads to an optimal starting point for a plausible medicinal chemistry approach for this novel strategy.